Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: Case Western Reserve University, Beachwood, Ohio
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates
Genetic Epidemiology of Rotator Cuff Tears: the CuffGEN Study
NCT04831164
Recruiting
Rotator cuff tear is one of the most common reasons to seek musculoskeletal care, and cuff repair is one of the fastest growing ambulatory surgery procedures. However, the etiology of cuff tears, reasons for variability treatment success, and causes of FI are poorly understood. A large-scale genome-wide association studies (GWAS) using imaging-verified rotator cuff tear cases and controls can address limitations in rigor of prior research and assess the genetic basis of FI and functional outcome... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
11/17/2024
Locations: Ohio State University, Columbus, Ohio
Conditions: Rotator Cuff Tears
Register for Updates
Endoscopic Myotomy of the Pylorus to Improve Emptying and Symptoms Trial
NCT05039424
Recruiting
A randomized clinical trial comparing endoscopic per-oral pyloromyotomy (POP) versus a control sham intervention (diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption) in patients with medically refractory gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/15/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Gastroparesis
Register for Updates
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
NCT03763643
Recruiting
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
11/15/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
The Myelin Disorders Biorepository Project
NCT03047369
Recruiting
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies,... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, Aicardi Goutieres Syndrome, Metachromatic Leukodystrophy, TUBB4A-Related Leukodystrophy, 4H Syndrome, Krabbe Disease, Alexander Disease, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Adrenomyeloneuropathy, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy With Subcortical Cysts, Vanishing White Matter Disease, Cockayne Syndrome, Labrune Syndrome, ADLD, Gangliosidoses, Peroxisomal Biogenesis Disorder, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, AGS, Alexanders Leukodystrophy, AxD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, GALC Deficiency, Globoid Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, MLD, PMD, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, GM2 Gangliosidosis, BPAN, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Register for Updates
WBV and Serial Casting for Children with Cerebral Palsy
NCT06693388
Recruiting
Children with cerebral palsy have increased muscle tone which often results in decreased active and passive movement at the ankle. While many management strategies exist (including passive stretching, WBV, serial casting, Botox, and surgical tendon lengthening), the utilization of WBV in combination with active exercises and serial casting has not been previously explored. Serial casting is the repeated application of a fiberglass cast (such as that applied to manage stable fractures) on a sched... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
11/14/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Cerebral Palsy (CP), Cerebral Palsy
Register for Updates
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
NCT05860296
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Register for Updates
A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)
NCT05795465
Recruiting
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/14/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Respiratory Distress Syndrome, Acute
Register for Updates
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882
Recruiting
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/14/2024
Locations: Vanda Investigational Site, Cincinnati, Ohio
Conditions: Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders
Register for Updates
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
NCT06690801
Recruiting
The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk s... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
11/13/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Acute Respiratory Distress Syndrome
Register for Updates
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275
Recruiting
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Register for Updates
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
Recruiting
This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide may have antineoplastic activity which may help block the formation o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Register for Updates